ACRS Q1 2019 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$407M

Q1 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$5M+350.9% YoY

Gross Profit

$2M44.9% margin

Operating Income

-$37M-740.6% margin

Net Income

-$38M-745.2% margin

EPS (Diluted)

$-0.91

QoQ Revenue Growth

+37.4%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$32M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$253M

Total Liabilities

$71M

Stockholders' Equity

$182M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$1M	+350.9%
Gross Profit	$2M	$151,000	+1399.3%
Operating Income	-$37M	-$31M	-20.6%
Net Income	-$38M	-$30M	-24.3%

Revenue Segments

Product

$4M50%

Rhofade Product

$4M49%

Eskata Product

$72,0001%